Artículos por temáticas

Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients

Gauthier S, Rosa-Neto P, Kass JS.

Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):615-8. doi: 10.1212/CON.0000000000000306.

[Research progress in pharmacological effects of Uncaria Hook on Alzheimer disease models]

Liu L, Zhao YH, Zeng CQ, Zeng Y.

Yao Xue Xue Bao. 2016 Apr;51(4):536-42.

Flashbulb memories of Paris attacks: Recall of these events and subjective reliving of these memories in a case with Alzheimer disease

El Haj M, Gandolphe MC, Wawrziczny E, Antoine P.

Medicine (Baltimore). 2016 Nov;95(46):e5448. doi: 10.1097/MD.0000000000005448.

Pressure ulcers induced by drug administration: A new concept and report of four cases in elderly patients

Mizokami F, Takahashi Y, Hasegawa K, Hattori H, Nishihara K, Endo H, Furuta K, Isogai Z.

J Dermatol. 2016 Apr;43(4):436-8. doi: 10.1111/1346-8138.13093. Epub 2015 Sep 14.

Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria

Grundman M, Johnson KA, Lu M, Siderowf A, Dell'Agnello G, Arora AK, Skovronsky DM, Mintun MA, Pontecorvo MJ; 18F-AV-45-A17 Study Group.

Dement Geriatr Cogn Disord. 2016;41(1-2):80-92. doi: 10.1159/000441139. Epub 2016 Jan 8.

Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation

Kudoh C, Arita R, Honda M, Kishi T, Komatsu Y, Asou H, Mimura M.

Psychogeriatrics. 2016 Mar;16(2):85-92. doi: 10.1111/psyg.12125. Epub 2015 Apr 27.

Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device

Eyjolfsdottir H, Eriksdotter M, Linderoth B, Lind G, Juliusson B, Kusk P, Almkvist O, Andreasen N, Blennow K, Ferreira D, Westman E, Nennesmo I, Karami A, Darreh-Shori T, Kadir A, Nordberg A, Sundströ

Alzheimers Res Ther. 2016 Jul 7;8(1):30. doi: 10.1186/s13195-016-0195-9.

Protein Kinase C Activation as a Potential Therapeutic Strategy in Alzheimer's Disease: Is there a Role for Embryonic Lethal Abnormal Vision-like Proteins?

Talman V, Pascale A, Jäntti M, Amadio M, Tuominen RK.

Basic Clin Pharmacol Toxicol. 2016 Aug;119(2):149-60. doi: 10.1111/bcpt.12581. Epub 2016 Apr 29.

[Preventive effects of curcumin and resveratrol in Alzheimer’s disease]

Tęcza P, Żylińska L.

Przegl Lek. 2016;73(5):320-3.

Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies

Ivanoiu A, Pariente J, Booth K, Lobello K, Luscan G, Hua L, Lucas P, Styren S, Yang L, Li D, Black RS, Brashear HR, McRae T.

Alzheimers Res Ther. 2016 Jun 23;8(1):24. doi: 10.1186/s13195-016-0193-y.

Role of docosahexaenoic acid in the modulation of glial cells in Alzheimer's disease

Heras-Sandoval D, Pedraza-Chaverri J, Pérez-Rojas JM.

J Neuroinflammation. 2016 Mar 10;13(1):61. doi: 10.1186/s12974-016-0525-7.

Drug use in persons with and without Alzheimer's disease aged 90 years or more

Taipale H, Koponen M, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S.

Age Ageing. 2016 Nov;45(6):900-904. doi: 10.1093/ageing/afw141. Epub 2016 Sep 8.

The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis

Cheng H, Shang Y, Jiang L, Shi TL, Wang L.

Int J Neurosci. 2016;126(4):299-307. doi: 10.3109/00207454.2015.1015722. Epub 2015 May 22.

Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily)

Zhang ZX, Hong Z, Wang YP, He L, Wang N, Zhao ZX, Zhao G, Shang L, Weisskopf M, Callegari F, Strohmaier C.

CNS Neurosci Ther. 2016 Jun;22(6):488-96. doi: 10.1111/cns.12521. Epub 2016 Mar 25.

Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic-naïve Alzheimer's disease patients

Lee YM, Park JM, Lee BD, Moon E, Jeong HJ, Chung YI, Kim JH, Kim HJ, Mun CW, Kim TH, Kim YH.

J Clin Psychiatry. 2016 Jan;77(1):e8-13. doi: 10.4088/JCP.14m09740.